These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 25844949)
1. The development and manufacture of influenza vaccines. Buckland BC Hum Vaccin Immunother; 2015; 11(6):1357-60. PubMed ID: 25844949 [TBL] [Abstract][Full Text] [Related]
2. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Buckland B; Boulanger R; Fino M; Srivastava I; Holtz K; Khramtsov N; McPherson C; Meghrous J; Kubera P; Cox MM Vaccine; 2014 Sep; 32(42):5496-502. PubMed ID: 25131727 [TBL] [Abstract][Full Text] [Related]
3. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Hegde NR Hum Vaccin Immunother; 2015; 11(5):1223-34. PubMed ID: 25875691 [TBL] [Abstract][Full Text] [Related]
4. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. Lu B; Zhou H; Ye D; Kemble G; Jin H J Virol; 2005 Jun; 79(11):6763-71. PubMed ID: 15890915 [TBL] [Abstract][Full Text] [Related]
5. The large-scale production of an artificial influenza virus-like particle vaccine in silkworm pupae. Nerome K; Sugita S; Kuroda K; Hirose T; Matsuda S; Majima K; Kawasaki K; Shibata T; Poetri ON; Soejoedono RD; Mayasari NL; Agungpriyono S; Nerome R Vaccine; 2015 Jan; 33(1):117-25. PubMed ID: 25448101 [TBL] [Abstract][Full Text] [Related]
6. Development and strategies of cell-culture technology for influenza vaccine. Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703 [TBL] [Abstract][Full Text] [Related]
8. Bringing influenza vaccines into the 21st century. Settembre EC; Dormitzer PR; Rappuoli R Hum Vaccin Immunother; 2014; 10(3):600-4. PubMed ID: 24378716 [TBL] [Abstract][Full Text] [Related]
9. MDCK cell-cultured influenza virus vaccine protects mice from lethal challenge with different influenza viruses. Liu K; Yao Z; Zhang L; Li J; Xing L; Wang X Appl Microbiol Biotechnol; 2012 Jun; 94(5):1173-9. PubMed ID: 22415544 [TBL] [Abstract][Full Text] [Related]
10. FluBlok, a next generation influenza vaccine manufactured in insect cells. Cox MM; Hollister JR Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194 [TBL] [Abstract][Full Text] [Related]
11. Increase in viral yield in eggs and MDCK cells of reassortant H5N1 vaccine candidate viruses caused by insertion of 38 amino acids into the NA stalk. Zhang W; Xue T; Wu X; Zhang P; Zhao G; Peng D; Hu S; Wang X; Liu X; Liu W; Liu X Vaccine; 2011 Oct; 29(45):8032-41. PubMed ID: 21864614 [TBL] [Abstract][Full Text] [Related]
12. CAP, a new human suspension cell line for influenza virus production. Genzel Y; Behrendt I; Rödig J; Rapp E; Kueppers C; Kochanek S; Schiedner G; Reichl U Appl Microbiol Biotechnol; 2013 Jan; 97(1):111-22. PubMed ID: 22821436 [TBL] [Abstract][Full Text] [Related]
13. Improving influenza virus backbones by including terminal regions of MDCK-adapted strains on hemagglutinin and neuraminidase gene segments. Gomila RC; Suphaphiphat P; Judge C; Spencer T; Ferrari A; Wen Y; Palladino G; Dormitzer PR; Mason PW Vaccine; 2013 Oct; 31(42):4736-43. PubMed ID: 23973324 [TBL] [Abstract][Full Text] [Related]
14. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor. Sun B; Yu X; Kong W; Sun S; Yang P; Zhu C; Zhang H; Wu Y; Chen Y; Shi Y; Zhang X; Jiang C Appl Microbiol Biotechnol; 2013 Feb; 97(3):1063-70. PubMed ID: 22945265 [TBL] [Abstract][Full Text] [Related]
15. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M Vaccine; 2011 Oct; 29(44):7733-9. PubMed ID: 21835220 [TBL] [Abstract][Full Text] [Related]
16. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines. Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718 [TBL] [Abstract][Full Text] [Related]
17. Bioprocess optimization for cell culture based influenza vaccine production. Aggarwal K; Jing F; Maranga L; Liu J Vaccine; 2011 Apr; 29(17):3320-8. PubMed ID: 21335031 [TBL] [Abstract][Full Text] [Related]
18. The influenza vaccine innovation system and lessons for PDPs. Huzair F Hum Vaccin Immunother; 2012 Mar; 8(3):407-10. PubMed ID: 22327495 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456 [TBL] [Abstract][Full Text] [Related]
20. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]